Advertisement
Representing the next generation in bifurcation stenting, the Antares(TM)system has potential use in a quarter of the 2.2 million angioplastyprocedures performed annually worldwide. Antares(TM) stents are not yetapproved in the United States and are limited by Federal law toinvestigational use.
Advertisement
"We are very pleased to achieve this significant milestone that allowscommercialization of our Antares(TM) stent system in Europe," said EitanKonstantino, PhD, President and Chief Executive Officer of TMI. "We believethat the Antares(TM) stent system represents a breakthrough in the treatmentof patients suffering from coronary artery disease at or near bifurcations.
"I like the Antares(TM) system concept. The system is designed to fit allclasses of bifurcation lesions, irrespective of the size and angulation of theside-branch," said Professor Carlo Di Mario from Royal Brompton Hospital inLondon. "The operator does not need to commit to a pre-determined side branchtreatment and has the flexibility to do what is right for the patient."
Lesions at or near side branches in the coronary tree pose multiplechallenges to interventional cardiologists. Combining a low profile stentwith a proprietary delivery system, the Antares(TM) system provides a uniqueset of solutions to the challenges of bifurcation stenting. It can bedelivered and deployed in a single step while maintaining access to the sidebranch and scaffolding the ostium, or the origin of the side branch. As aresult, the cardiologist has greater flexibility of treatment options, withthe freedom to deploy a second stent in the side branch when additionalsupport is necessary.
"The Antares(TM) stent system is an elegant solution to treat bifurcationlesions that is focused on the main vessel," observed Alexandre Abizaid, MD,PhD, Chief of Coronary Interventions at the Institute Dante Pazzanese ofCardiology in Sao Paulo, Brazil. Dr. Abizaid continued, "It increasesoperators' confidence by providing continuous side branch access throughoutthe procedure."
About TriReme Medical Inc.
TriReme Medical Inc. (TMI) is a privately held medical device companybacked by Three Arch Partners and Adams Street Partners. TMI is based inCalifornia and dedicated to the development and manufacturing of novel stenttechnology for the treatment of atherosclerotic disease at or nearbifurcations.
SOURCE TriReme Medical Inc.
